Softwr

Healthcare · head to head

Annalise.ai vs Sysmex

Annalise.ai logo

Annalise.ai

Healthcare

Multi-finding chest X-ray and head CT triage AI with FDA clearance on named findings, not on the whole model

From
On request
Rated
-
Full reviewWebsite
Sysmex logo

Sysmex

Healthcare

Haematology and urinalysis analysers sold with the middleware that decides which results a scientist ever sees

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Annalise.ai the United States cleared indication covers roughly ten findings for triage and notification, far fewer than the model reports, so a buyer who evaluates the full multi-finding output and then contracts in the United States gets a much narrower cleared use.; Sysmex the middleware is not realistically separable from the instrument contract, so a laboratory that likes Caresphere but wants another vendor analyser has no clean path to buying just the software.
  • They diverge on capability: Annalise.ai covers Annalise Enterprise CXR, Sysmex covers Caresphere autovalidation.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Annalise.ai and Sysmex actually diverge.

Attributes where Annalise.ai and Sysmex differ
AttributeAnnalise.aiSysmex
PlatformsWeb, Cloud, On-premiseWeb, Windows, On-premise

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Annalise.ai

  • Annalise Enterprise CXR
  • Annalise Enterprise CTB
  • Triage and notification
  • Worklist reprioritisation
  • Localisation overlays
  • Confidence output
  • PACS-native deployment
  • On-premise or cloud inference

Only in Sysmex

  • Caresphere autovalidation
  • Delta and moving average QC
  • WAM rule sets
  • Fleet telemetry
  • Reagent inventory tracking
  • Extended white cell parameters
  • LIS interfacing
  • Multi-site harmonisation

What people use each for

The jobs each tool is most often brought in to do.

Annalise.ai

  • An emergency department wanting pneumothorax and intracranial haemorrhage pushed to the front of the reading queue overnight when cover is thinnestnot Sysmex
  • A teleradiology provider covering many small hospitals that needs consistent triage before a human readsnot Sysmex
  • A screening programme in Europe where the broader CE marked decision support indication, rather than the narrow United States triage clearance, is what is being deployednot Sysmex
  • A radiology department building an AI governance programme that wants one vendor covering both chest radiograph and head CT rather than contracting two separate algorithm suppliersnot Sysmex

Sysmex

  • A hospital network standardising full blood count reporting across six laboratories so a result released at a district hospital carries the same rules as the tertiary centrenot Annalise.ai
  • A pathology group trying to raise autovalidation rates to absorb rising demand without recruiting more biomedical scientistsnot Annalise.ai
  • A blood sciences service consolidating haematology, coagulation and urinalysis onto one middleware layer to remove three separate QC workflowsnot Annalise.ai
  • A laboratory running 24 hour service that needs remote analyser telemetry so an overnight fault is triaged before the morning shift arrivesnot Annalise.ai

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Annalise.ai

  • The United States cleared indication covers roughly ten findings for triage and notification, far fewer than the model reports, so a buyer who evaluates the full multi-finding output and then contracts in the United States gets a much narrower cleared use.
  • Triage AI reprioritises a worklist but does not change clinical decisions on its own, so departments that do not redesign how urgent studies are picked up see no measurable improvement in time to treatment.
  • Published validation is largely reader study evidence on detection of individual findings; prospective evidence of shorter time to treatment in routine emergency care is thin.
  • The Annalise brand is being migrated under the Harrison.ai name for the critical care offering, which creates ambiguity in multi-year contracts about what product name is actually being supported.
  • A high finding count raises the alert burden, and departments report that low prevalence findings generate false positives that erode radiologist trust unless the alerting thresholds are tuned locally.

Sysmex

  • The middleware is not realistically separable from the instrument contract, so a laboratory that likes Caresphere but wants another vendor analyser has no clean path to buying just the software.
  • Reagent rental agreements set a minimum annual test volume, and a laboratory whose activity falls after a service reconfiguration keeps paying against a floor it no longer reaches.
  • Regulatory clearance is granted per parameter and per region, so a flag or extended parameter that a European laboratory relies on may not be released for clinical use on the same analyser in the United States.
  • Interfacing to a non-Sysmex laboratory information system is a project, not a configuration step, and integration effort is often quoted separately from the instrument contract.
  • Autovalidation rule sets are configured locally, so the gains depend entirely on whether the laboratory has the clinical governance capacity to write, validate and audit those rules; buying the software does not deliver the saving on its own.

Pricing, plan by plan

Annalise.ai

On request
  • Annalise Enterprise$undefined/year
    • Priced per study analysed or as an annual volume subscription
    • CXR and CTB licensed separately
    • Cleared finding set differs by market, which changes what you are buying

Sysmex

On request
  • Reagent rental or cost per reportable result contract$undefined/year
    • Analyser hardware, reagents, service and Caresphere middleware bundled into a price per test
    • Five to seven year term typical
    • Minimum annual test volume commitment

Which should you pick?

Choose Annalise.ai if

  • You need annalise enterprise cxr.
  • You work on Web, Cloud, On-premise.
  • You also want annalise enterprise ctb.
Annalise.ai review

Choose Sysmex if

  • You need caresphere autovalidation.
  • You work on Web, Windows, On-premise.
  • You also want delta and moving average qc.
Sysmex review

Questions people ask

Is Annalise.ai or Sysmex better?
Neither clearly leads. Annalise.ai starts at On request and Sysmex at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Annalise.ai or Sysmex?
Annalise.ai starts at On request and Sysmex at On request.
Does Annalise.ai or Sysmex run on more platforms?
Annalise.ai runs on Web, Cloud, On-premise. Sysmex runs on Web, Windows, On-premise.
What is Annalise.ai best used for?
Annalise.ai is most often used for an emergency department wanting pneumothorax and intracranial haemorrhage pushed to the front of the reading queue overnight when cover is thinnest, a teleradiology provider covering many small hospitals that needs consistent triage before a human reads, a screening programme in europe where the broader ce marked decision support indication, rather than the narrow united states triage clearance, is what is being deployed, a radiology department building an ai governance programme that wants one vendor covering both chest radiograph and head ct rather than contracting two separate algorithm suppliers. Of those, an emergency department wanting pneumothorax and intracranial haemorrhage pushed to the front of the reading queue overnight when cover is thinnest and a teleradiology provider covering many small hospitals that needs consistent triage before a human reads are not what Sysmex is typically brought in for.
What can Annalise.ai do that Sysmex cannot?
Annalise.ai covers Annalise Enterprise CXR, Annalise Enterprise CTB, Triage and notification, Worklist reprioritisation. Sysmex covers Caresphere autovalidation, Delta and moving average QC, WAM rule sets, Fleet telemetry.

Answered from the vendors’ own pages

Annalise.ai: How many findings are FDA cleared?

Around ten across chest X-ray and head CT, for triage and notification only. The model reports far more findings than that; the rest are not cleared in the United States.

Sysmex: Can I buy Caresphere without Sysmex analysers?

Not in practice. It is licensed as part of the instrument and reagent agreement, and its value depends on Sysmex-specific parameters and flags.

Annalise.ai: Is the European position different?

Yes. CE marking under the medical device regulation covers a broader decision support indication than the United States triage and notification clearances, so the same software is a different regulatory product depending on where you deploy it.

Sysmex: Is Sysmex software FDA cleared?

Clearance attaches to the analysers and to individual reported parameters, not to the middleware as a whole. Check the specific parameter and the specific market, because clearances differ between the United States, Europe and Japan.

Annalise.ai: Does it diagnose?

No. In the United States it is a triage and notification device: it flags studies for earlier review, and the radiologist makes the diagnosis.

Sysmex: How is it priced?

Per reportable result, or as a reagent rental with a minimum annual volume. There is no per user or per seat price.

Annalise.ai: Is Annalise.ai becoming Harrison.ai?

The critical care offering is now marketed under the Harrison.ai name. Ask the vendor to name the contracted product explicitly before signing a multi-year deal.

Sysmex: What is the contract length?

Typically five to seven years, aligned to instrument depreciation, with reagent pricing fixed or indexed over the term.

Share

Related pages

More on Annalise.ai

More on Sysmex

Keep looking

Other head to heads